NCT02442687View on ClinicalTrials.gov

JKB-121 for the Treatment of Nonalcoholic Steatohepatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

August 1, 2015

Primary Completion Date

September 24, 2017

Study Completion Date

September 24, 2017

Conditions
Nonalcoholic Steatohepatitis
Interventions
DRUG

JKB-121: 5 mg twice daily

DRUG

JKB-121: 10 mg twice daily

DRUG

Placebo

Trial Locations (8)

22903

University of Virginia Health Systems, Charlottesville

23298

Medical College of Virginia, Richmond

27710

Duke University, Durham

36305

Digestive Disease Specialists of the Southeast, Dothan

45219

Digestive Disease Specialists, Cincinnati

60611

Northwestern University Feinberg School of Medicine, Chicago

78234

Brook Army Medical Center, Houston

89102

Digestive Associates, Las Vegas

All Listed Sponsors
lead

Manal Abdelmalek

OTHER

NCT02442687 - JKB-121 for the Treatment of Nonalcoholic Steatohepatitis | Biotech Hunter | Biotech Hunter